HARP: Harpoon Therapeutics Corp Cash Calculated per Single Share

Harpoon Therapeutics Corp - graphic logo of issuer HARP

Harpoon Therapeutics (HARP) develops unique TriTAC antibodies that link tumors and T-cells to combat cancer. Revenues are based on the supply of carcinoma therapy drugs to oncology clinics. Cash per share demonstrates financial stability, with the value of 1.47 serving as the current metric. Growth prospects depend on the long-term results of late-stage clinical trials.

Harpoon Therapeutics (HARP) - Cash per Share from 07/04/2022 to 03/16/2024

Comprehensive metric breakdowns and analytics for harpoontx.com (HARP)

- current quotes and average value forecast:
- cash availability and cash flow indicators:
Comprehensive company analysis:Harpoon Therapeutics (HARP)
Flagship merchandise of Harpoon Therapeutics

Harpoon Therapeutics focuses on developing anticancer immunotherapies without current operating revenue. The 1.47 metric reflects the share of liquid assets per common share. This metric allows for an assessment of the company's financial cushion to continue costly clinical trials. It is critical for investors to monitor the burn rate until the drugs reach commercialization. The price action of cash per share clearly demonstrates the current pace of cash burn.